Core Insights - DexCom, Inc. (NASDAQ:DXCM) is a leading company in the medical device sector, focusing on continuous glucose monitoring (CGM) systems for diabetes management, competing with firms like Abbott Laboratories and Medtronic [1] Stock Performance - Over the past 30 days, DXCM has experienced a modest gain of 1.16%, indicating positive investor interest, although there was a recent decline of 3.43% over the last 10 days, which may present a strategic entry point for investors [2] Growth Potential - The company has a projected growth potential of 22.52%, reflecting strong fundamentals and market position, which are essential for investors seeking significant returns [3] Financial Health - DexCom holds a Piotroski Score of 8, indicating robust financial health in terms of profitability, leverage, liquidity, and operating efficiency, making it an appealing option for long-term investors [4][6] Target Price - The target price for DXCM is set at $85.82, serving as a benchmark for investors and reflecting the stock's potential for growth driven by solid fundamentals and market dynamics [5]